Intarcia Therapeutics of Emeryville, Ca. has pulled its IPO, reportedly citing market conditions. Intarcia had planned to sell 5 million shares at $12 to $14 a share. Intarcia's pipeline includes a combination therapy for the treatment of hormone dependent breast cancer in postmenopausal women and an implant to deliver omega interferon for the treatment of hepatitis C.
- read this release for more